



© Copyright 2012 Oregon State University. All Rights Reserved

Drug Use Research & Management Program
OHA Division of Medical Assistance Programs
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119



Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, April 4, 2024 1:00 - 5:00 PM

Remote Meeting via Zoom Platform

MEETING AGENDA

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333.

I. CALL TO ORDER

- | | | |
|---------|-------------------------------------|-----------------|
| 1:00 PM | A. Roll Call & Introductions | R. Citron (OSU) |
| | B. Conflict of Interest Declaration | R. Citron (OSU) |
| | C. Approval of Agenda and Minutes | R. Citron (OSU) |
| | D. Department Update | A. Gibler (OHA) |
| | E. Legislative update | D. Weston (OHA) |

1:20 PM II. CONSENT AGENDA TOPICS S. Ramirez (Chair)

- A. Vascular Endothelial Growth Factor Class Update and New Drug Evaluation
- B. Insulins Literature Scan
- C. PDL OLD BUSINESS: Inhalers for Asthma and COPD Class Update
- D. Oncology Prior Authorization Updates
 - 1. Public Comment

III. DUR NEW BUSINESS

- | | | |
|---------|---|-------------------|
| 1:25 PM | A. Orphan Drug Policy Updates | S. Servid (OSU) |
| | 1. Prior Authorization Criteria | |
| | 2. Public Comment | |
| | 3. Discussion and Clinical Recommendations to OHA | |
| 1:30 PM | B. Tepezza® (Teprotumumab) Prior Authorization Update | S. Fletcher (OSU) |
| | 1. Prior Authorization Criteria | |
| | 2. Public Comment | |
| | 3. Discussion and Clinical Recommendations to OHA | |

IV. PREFERRED DRUG LIST NEW BUSINESS

- | | | |
|---------|---|------------------|
| 1:40 PM | C. Drugs for Weight Loss DERP Summary and GLP-1 Receptor Agonists Literature Scan | |
| | 1. Weight Loss Coverage State Plan Overview | D. Weston (OHA) |
| | 2. GLP-1 Receptor Agonists Literature Scan | K. Sentena (OSU) |

| | | |
|---------|---|-----------------|
| | <ul style="list-style-type: none"> 3. Weight Loss DERP Summary/Prior Authorization Criteria 4. Public Comment 5. Discussion and Clinical Recommendations to OHA | |
| 2:20 PM | D. Drugs for Bowel Prep Class Review <ul style="list-style-type: none"> 1. Class Review 2. Public Comment 3. Discussion and Clinical Recommendations to OHA | D. Moretz (OSU) |
| 2:35 PM | E. Antivirals for SARS-CoV2 Class Review <ul style="list-style-type: none"> 1. Class Review 2. Public Comment 3. Discussion and Clinical Recommendations to OHA | D. Moretz (OSU) |
| 2:55 PM | BREAK | |
| 3:10 PM | F. Syfovre® (pegcetacoplan) and Izervay™ (avacincaptad pegol) New Drug Evaluations <ul style="list-style-type: none"> 1. New Drug Evaluations/Prior Authorization Criteria 2. Public Comment 3. Discussion and Clinical Recommendations to OHA | D. Engen (OSU) |
| 3:30 PM | G. Phosphorus Binder Class Update and New Drug Evaluation <ul style="list-style-type: none"> 1. Class Update/Prior Authorization Criteria 2. Xphozah® (tenapanor) New Drug Evaluation 3. Public Comment 4. Discussion and Clinical Recommendations to OHA | D. Moretz (OSU) |
| 3:50 PM | V. EXECUTIVE SESSION | |
| 4:50 PM | VI. RECONVENE for PUBLIC RECOMMENDATIONS | |
| | VII. ADJOURN | |